Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sohail Saleem

Nephrology Gainesville, GA Medical Doctor

NPI 1932102993 CMS profile 86891

663 Lanier Park Dr, Gainesville, GA 30501

Open in the dashboard

General payments

$4,455

253 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sohail Saleem of Gainesville, GA is reported in the CMS Open Payments database as having received $4,455 across 253 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $935 45
2024 General $877 46
2023 General $646 33
2022 General $746 40
2021 General $828 59
2020 General $109 10
2019 General $314 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sohail Saleem
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Sohail Saleem were reported at $935. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Sohail Saleem Nephrology median Middle half National median
2019 $314 $236 $90–$588 $163
2020 $109 $135 $46–$364 $114
2021 $828 $202 $67–$551 $132
2022 $746 $242 $77–$695 $149
2023 $646 $254 $84–$766 $160
2024 $877 $300 $99–$852 $164
2025 $935 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $682 36 payments
  2. Otsuka America Pharmaceutical, Inc. $643 35 payments
  3. Amgen Inc. $473 23 payments
  4. Relypsa, Inc. $423 23 payments
  5. Fresenius USA Marketing, Inc. $408 24 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $374 21 payments
  7. Retrophin, Inc. $299 23 payments
  8. Daiichi Sankyo Inc. $194 11 payments
  9. Aurinia Pharma U.S., Inc. $166 10 payments
  10. Novartis Pharmaceuticals Corporation $153 9 payments
  11. Other $641 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,286 230 payments
  2. Education $168 23 payments
Products named General payments · program years 2019–2025
  1. JYNARQUE $572 31 payments
  2. FARXIGA $423 21 payments
  3. Kerendia $374 21 payments
  4. Velphoro $275 17 payments
  5. LOKELMA $246 14 payments
  6. Veltassa $244 14 payments
  7. TAVNEOS $216 11 payments
  8. INJECTAFER $180 10 payments
  9. LUPKYNIS $166 10 payments
  10. Auryxia $110 7 payments
  11. Other $1,332 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,316

Median for Nephrology: 954

Drug cost

$56,323

Median for Nephrology: $127,050

Branded share of claims

8.6%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 26 $19,383
Sevelamer Carbonate Generic 68 $9,894
Lokelma Sodium Zirconium Cyclosilicate Brand 18 $8,954
Potassium Citrate Er Potassium Citrate Brand 49 $3,930
Calcium Acetate Generic 14 $1,493
Nifedipine Er Nifedipine Brand 20 $1,307
Hydralazine Hcl Generic 89 $1,092
Calcitriol Generic 111 $1,085
Valsartan Generic 35 $977
Potassium Chloride Generic 97 $888

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$124,473

Medicare's payments for the services billed

Medicare patients

449

Average age 75

Services billed

1,873

209 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Heart failure 58%
Diabetes 57%
Ischemic heart disease 54%
Arthritis 49%
Atrial fibrillation 38%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $184
$184 26 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $80
$80 — —
Velphoro
  • Fresenius USA Marketing, Inc. $66
$66 — —
TAVNEOS
  • Amgen Inc. $65
$65 — —
JYNARQUE
  • Otsuka America Pharmaceutical, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

253 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record